These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 32479195)
41. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment]. Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575 [TBL] [Abstract][Full Text] [Related]
42. Inclisiran-New hope in the management of lipid disorders? Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073 [TBL] [Abstract][Full Text] [Related]
43. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease]. Thiery J; Burkhardt R Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417 [TBL] [Abstract][Full Text] [Related]
44. Familial hypercholesterolemia treatments: Guidelines and new therapies. Raal FJ; Hovingh GK; Catapano AL Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089 [TBL] [Abstract][Full Text] [Related]
45. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441 [TBL] [Abstract][Full Text] [Related]
46. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
48. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Ruel I; Aljenedil S; Sadri I; de Varennes É; Hegele RA; Couture P; Bergeron J; Wanneh E; Baass A; Dufour R; Gaudet D; Brisson D; Brunham LR; Francis GA; Cermakova L; Brophy JM; Ryomoto A; Mancini GBJ; Genest J Clin Chem; 2018 Feb; 64(2):355-362. PubMed ID: 29038147 [TBL] [Abstract][Full Text] [Related]
49. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088 [TBL] [Abstract][Full Text] [Related]
50. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937 [TBL] [Abstract][Full Text] [Related]
51. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067 [TBL] [Abstract][Full Text] [Related]
52. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. O'Keefe JH; DiNicolantonio JJ; Lavie CJ Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940 [TBL] [Abstract][Full Text] [Related]
53. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068 [TBL] [Abstract][Full Text] [Related]
54. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841 [TBL] [Abstract][Full Text] [Related]
55. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study. Miyoshi T; Nakamura K; Doi M; Ito H Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669 [TBL] [Abstract][Full Text] [Related]